Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kintor Pharmaceutical Ltd ( (HK:9939) ) has provided an update.
Kintor Pharmaceutical has signed an exclusive sales agency agreement under which its wholly owned subsidiary Koshine Hong Kong will partner with Beijing Dekai Pharmaceutical Technology to market and promote Kintor’s anti-hair loss foam product in mainland China. By leveraging Dekai’s extensive chronic disease user base, online healthcare community, and strong minoxidil market presence, together with Kintor’s product advantages in foam-based, propylene-glycol-free hair loss treatment, the collaboration aims to accelerate commercialization, broaden distribution channels, and strengthen Kintor’s competitive positioning in the fast-growing Chinese hair care and cosmetic therapeutics market.
The most recent analyst rating on (HK:9939) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Kintor Pharmaceutical Ltd stock, see the HK:9939 Stock Forecast page.
More about Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited is a Hong Kong–listed biopharmaceutical company focused on developing and commercializing innovative therapies, including cosmetic and dermatological products such as anti-hair loss formulations, with an increasing emphasis on expanding product penetration in the Chinese mainland and overseas consumer markets.
Average Trading Volume: 1,583,883
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.17B
Find detailed analytics on 9939 stock on TipRanks’ Stock Analysis page.